DOT1L Inhibitor Composition for Ebola Viral Load Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective treatments for viral diseases such as Ebola, with no FDA-approved drugs and limited treatment options, especially for RNA viruses that are fatal or have unknown strains and genetic variants.
Innovation Solution
A pharmaceutical composition including DOT1L inhibitors like EPZ5676, SAHH inhibitors, and other compounds to reduce viral load by inhibiting S-adenosyl methionine formation, combined with TNF alpha inhibitors and collagen precursors to enhance endothelial barrier integrity and collagen generation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a single drug treatment or perfect fit immunological solution is used, then the treatment approach is simple and targeted, but it fails to provide effective treatment for multiple viral strains and genetic variants
Solution Approach 1:
The patent employs a multi-component pharmaceutical composition where each compound targets different stages of the viral replication cycle. This universal approach allows a single treatment formulation to address multiple viral strains and genetic variants simultaneously, transforming the limitation of strain-specific treatments into a broad-spectrum solution that maintains functional versatility across diverse viral threats.
Solution Approach 2:
The invention combines multiple antiviral compounds with distinct mechanisms of action into a composite pharmaceutical formulation. This composite strategy integrates compounds that inhibit viral entry, replication, assembly, and release processes, creating a synergistic treatment that overcomes the complexity of individual drug limitations while achieving enhanced broad-spectrum efficacy against RNA viruses including Ebola, Marburg, Dengue, and other filoviruses and flaviviruses.
2Reliability
If FDA approval processes are followed for new antiviral treatments, then treatment safety and efficacy are ensured, but the approval time and cost increase significantly
Solution Approach 1:
The patent utilizes compounds with established safety profiles and known mechanisms of action that have undergone prior preclinical and clinical evaluation. By selecting antiviral agents with existing regulatory familiarity and documented safety data, the formulation leverages preliminary actions already taken on individual components, thereby reducing the time and resource burden of de novo approval processes while maintaining reliable safety and efficacy standards through the established track records of constituent compounds.
3Productivity
If existing antiviral drugs are used, then treatment options are limited, but developing new drugs requires extensive research and testing
Solution Approach 1:
The patent merges multiple existing antiviral compounds into a unified pharmaceutical composition, each contributing distinct antiviral mechanisms. This combining strategy transforms limited individual drug options into a comprehensive treatment approach where compounds targeting different viral lifecycle stages work synergistically. The formulation integrates available antiviral agents with proven safety profiles, thereby increasing treatment availability and productivity without requiring extensive de novo research and development on entirely new molecular entities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces viral load by at least 50%, improving survival rates in mammalian subjects by inhibiting viral replication and enhancing endothelial barrier integrity, potentially reducing the need for FDA approval and providing a cost-effective treatment.
Implementation Method 1
the compound adapted to inhibit the formation of S-adenosyl methionine (SAM) in the virus, the compound being a DOT1L inhibitor
Implementation Method 2
the pharmaceutical composition includes an SAHH inhibitor and a DOT1L inhibitor
Implementation Method 3
the composition includes; a) an S-adenosyl homocysteine hydrolase (SAHH) inhibitor and a DOT1L inhibitor; and b) at least one TNF alpha inhibitor
Implementation Method 4
the pharmaceutical composition further includes at least one collagen precursor
Implementation Method 5
the composition effectively reduces viral load by at least 50%, improving survival rates in mammalian subjects by inhibiting viral replication
Data Source
AI summary
The present invention provides compounds and pharmaceutical compositions adapted to reduce a load of an RNA virus by at least 50%, the virus causing a pathogenic disease in a mammalian subject, the compound adapted to inhibit the formation of S-adenosyl methionine (SAM) in the virus, the compound being a DOTIL inhibitor, wherein the compound has a molecular weight of less than 1000, and a therapeutic index (TI= ED50/LD50) greater than 30 in the mammalian subject.